دورية أكاديمية
أعرض في EDS

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان: Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma.
المؤلفون: Ho CM; Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan.; Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan.; Institute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, 1001 University Road, Hsinchu 300, Taiwan., Lin KT; Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan., Shen R; Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan., Gu DL; Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan., Lee SS; Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan.; Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 115, Taiwan., Su WH; Department of Biomedical Sciences, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung Molecular Medicine Research Center, Chang Gung University, 259 Wen-Hua 1st Road, Kweishan, Taoyuan 333, Taiwan.; Department of Otolaryngology, Chang Gung Memorial Hospital, Linkou, 5 Fu-Hsing Street, Kweishan, Taoyuan 333, Taiwan., Jou YS; Institute of Biomedical Sciences, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan.; Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei 115, Taiwan.; Program in Molecular Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei 115, Taiwan.
المصدر: Computational and structural biotechnology journal [Comput Struct Biotechnol J] 2022 Apr 09; Vol. 20, pp. 1752-1763. Date of Electronic Publication: 2022 Apr 09 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology Country of Publication: Netherlands NLM ID: 101585369 Publication Model: eCollection Cited Medium: Print ISSN: 2001-0370 (Print) Linking ISSN: 20010370 NLM ISO Abbreviation: Comput Struct Biotechnol J Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology
Original Publication: Gothenburg, Sweden : Research Network of Computational and Structural Biotechnology
مستخلص: With the increasing incidence and mortality of human hepatocellular carcinoma (HCC) worldwide, revealing innovative targets to improve therapeutic strategies is crucial for prolonging the lives of patients. To identify innovative targets, we conducted a comprehensive comparative transcriptome analysis of 5,410 human HCCs and 974 mouse liver cancers to identify concordantly expressed genes associated with patient survival. Among the 664 identified prognostic comparative HCC (pcHCC) genes, upregulated pcHCC genes were associated with prognostic clinical features, including large tumor size, vascular invasion and late HCC stages. Interestingly, after validating HCC patient prognoses in multiple independent datasets, we matched the 664 aberrant pcHCC genes with the sorafenib-altered genes in TCGA_LIHC patients and found these 664 pcHCC genes were enriched in sorafenib-related functions, such as downregulated xenobiotic and lipid metabolism and upregulated cell proliferation. Therapeutic agents targeting aberrant pcHCC genes presented divergent molecular mechanisms, including suppression of sorafenib-unrelated oncogenic pathways, induction of sorafenib-unrelated ferroptosis, and modulation of sorafenib transportation and metabolism, to potentiate sorafenib therapeutic effects in HCC combination therapy. Moreover, the pcHCC genes NCAPG and CENPW, which have not been targeted in combination with sorafenib treatment, were knocked down and combined with sorafenib treatment, which reduced HCC cell viability based on disruption to the p38/STAT3 axis, thereby hypersensitizing HCC cells. Together, our results provide important resources and reveal that 664 pcHCC genes represent innovative targets suitable for developing therapeutic strategies in combination with sorafenib based on the divergent synergistic mechanisms for HCC tumor suppression.
Competing Interests: The authors declare no conflicts of interest.
(© 2022 The Authors.)
References: Lancet Oncol. 2018 Jul;19(7):940-952. (PMID: 29875066)
Cancer Cell. 2020 Sep 14;38(3):326-333. (PMID: 32750319)
Cell. 2017 Jun 15;169(7):1327-1341.e23. (PMID: 28622513)
Anticancer Drugs. 2022 Jan 1;33(1):e781-e783. (PMID: 34407053)
Int J Oncol. 2019 Apr;54(4):1398-1408. (PMID: 30720077)
Clin Cancer Res. 2012 Sep 1;18(17):4691-701. (PMID: 22811583)
Front Oncol. 2018 Dec 17;8:611. (PMID: 30619751)
J Surg Res. 2013 Nov;185(1):225-30. (PMID: 23769634)
Hepatology. 2010 May;51(5):1624-34. (PMID: 20209601)
J Cell Biochem. 2019 Feb 11;:. (PMID: 30746803)
N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514)
BMC Cancer. 2013 Nov 06;13:527. (PMID: 24195809)
Gut. 2017 Jul;66(7):1286-1296. (PMID: 27849562)
Biochem Biophys Res Commun. 1997 May 8;234(1):194-7. (PMID: 9168988)
J Surg Res. 2011 Sep;170(1):e85-92. (PMID: 21601879)
Zhonghua Gan Zang Bing Za Zhi. 2019 Jan 20;27(1):39-44. (PMID: 30685922)
Cancer Res. 2004 May 1;64(9):3030-6. (PMID: 15126338)
Cancer Res. 2016 Nov 1;76(21):6374-6381. (PMID: 27634755)
Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1203-8. (PMID: 14560154)
Nat Rev Clin Oncol. 2013 Mar;10(3):154-68. (PMID: 23358316)
Nat Genet. 2004 Dec;36(12):1306-11. (PMID: 15565109)
Clin Cancer Res. 2013 Mar 15;19(6):1458-66. (PMID: 23340295)
Nucleic Acids Res. 2007 Jan;35(Database issue):D727-31. (PMID: 17098932)
BMC Genomics. 2010 Dec 02;11 Suppl 4:S19. (PMID: 21143802)
Lancet Oncol. 2009 Jan;10(1):25-34. (PMID: 19095497)
J Mol Diagn. 2003 May;5(2):73-81. (PMID: 12707371)
Neoplasia. 2009 Sep;11(9):934-44. (PMID: 19724687)
J Biol Chem. 2002 Sep 13;277(37):33676-82. (PMID: 12087100)
Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648)
Cancers (Basel). 2019 Oct 25;11(11):. (PMID: 31731457)
Biochem Biophys Res Commun. 2019 Jul 5;514(4):1278-1284. (PMID: 31113615)
Onco Targets Ther. 2019 Oct 16;12:8537-8552. (PMID: 31802891)
Sci Rep. 2018 Jul 3;8(1):9997. (PMID: 29968763)
J Clin Gastroenterol. 2009 Feb;43(2):191-5. (PMID: 19142170)
Cell Death Dis. 2017 Oct 12;8(10):e3095. (PMID: 29022906)
Oncogene. 1999 Jul 1;18(26):3886-93. (PMID: 10445852)
Nucleic Acids Res. 2008 Jan;36(Database issue):D847-53. (PMID: 17916571)
Br J Cancer. 2013 Jan 15;108(1):72-81. (PMID: 23257894)
Genes Genomics. 2019 Feb;41(2):167-174. (PMID: 30267325)
N Engl J Med. 2019 Apr 11;380(15):1450-1462. (PMID: 30970190)
Exp Cell Res. 2001 Mar 10;264(1):100-10. (PMID: 11237526)
J Hepatol. 2010 Feb;52(2):220-7. (PMID: 20036025)
Lancet. 2018 Mar 24;391(10126):1163-1173. (PMID: 29433850)
Pathol Res Pract. 2017 Apr;213(4):316-321. (PMID: 28238542)
J Cancer. 2018 Jun 23;9(15):2678-2686. (PMID: 30087708)
Nature. 2010 Apr 15;464(7291):993-8. (PMID: 20393554)
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. (PMID: 23193258)
Anticancer Res. 2015 Apr;35(4):1985-95. (PMID: 25862851)
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9879-E9888. (PMID: 30287485)
Pharm Res. 2019 Aug 8;36(10):145. (PMID: 31396764)
Hepatology. 2013 Sep;58(3):1065-73. (PMID: 23532667)
Nucleic Acids Res. 2020 Jan 8;48(D1):D682-D688. (PMID: 31691826)
Dig Dis Sci. 2019 Apr;64(4):903-909. (PMID: 30863952)
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. (PMID: 31439937)
Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5. (PMID: 15508103)
Cancer Treat Res Commun. 2021;27:100328. (PMID: 33549983)
Biochem Pharmacol. 1995 Mar 30;49(7):873-81. (PMID: 7741759)
N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160)
Hepatology. 2013 Apr;57(4):1407-15. (PMID: 22890726)
FASEB J. 2017 Dec;31(12):5453-5465. (PMID: 28821631)
Genet Test Mol Biomarkers. 2019 Nov;23(11):766-777. (PMID: 31633428)
Cancer Chemother Pharmacol. 2018 May;81(5):853-862. (PMID: 29532153)
Carcinogenesis. 2000 Mar;21(3):371-7. (PMID: 10688857)
Nat Genet. 2005 Jan;37(1):48-55. (PMID: 15608639)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Neoplasia. 2011 Aug;13(8):704-15. (PMID: 21847362)
Cancer Discov. 2014 Jun;4(6):730-43. (PMID: 24687604)
Oncol Res. 2018 Mar 5;26(2):269-276. (PMID: 29046167)
Dig Dis Sci. 2014 Aug;59(8):1688-97. (PMID: 24573715)
Liver Int. 2019 Apr;39(4):714-726. (PMID: 30663219)
Cancer Chemother Pharmacol. 2013 May;71(5):1255-64. (PMID: 23435877)
Semin Cancer Biol. 2011 Feb;21(1):10-20. (PMID: 20969960)
J Hepatol. 2004 Feb;40(2):212-8. (PMID: 14739090)
Cancer Sci. 2016 Apr;107(4):507-13. (PMID: 26752068)
J Hepatol. 2019 Jul;71(1):78-90. (PMID: 30880225)
Int J Med Sci. 2019 Oct 21;16(12):1541-1548. (PMID: 31839741)
Nucleic Acids Res. 2016 May 5;44(8):e71. (PMID: 26704973)
Gastroenterology. 2001 Jun;120(7):1763-73. (PMID: 11375957)
J Clin Oncol. 2013 Apr 20;31(12):1592-605. (PMID: 23509311)
FASEB J. 2019 Aug;33(8):8759-8770. (PMID: 31022357)
Acta Pharmacol Sin. 2021 Feb;42(2):301-310. (PMID: 32699265)
Biochem J. 2000 Apr 1;347 Pt 1:89-96. (PMID: 10727406)
Hepatology. 2002 Mar;35(3):519-24. (PMID: 11870363)
Prostate. 2008 Oct 1;68(14):1517-30. (PMID: 18668517)
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224)
Cell Death Differ. 2020 Mar;27(3):1086-1104. (PMID: 31367013)
Cell. 2006 Jun 30;125(7):1253-67. (PMID: 16814713)
J Cancer Res Clin Oncol. 2008 May;134(5):535-41. (PMID: 17917742)
Transl Oncol. 2021 Nov;14(11):101201. (PMID: 34388691)
ScientificWorldJournal. 2013;2013:931972. (PMID: 23431262)
فهرسة مساهمة: Keywords: CENPW; CENPW, Centromere protein W; Comparative genomic analysis; DEG, Differential expression gene; Hepatocellular carcinoma; NCAPG; NCAPG, Non-SMC condensin I complex subunit G; Prognosis; Sorafenib combination therapy; TCGA_LIHC, The Cancer Genome Atlas_Liver Hepatocellular Carcinoma; pcHCC, Prognostic comparative hepatocellular carcinoma
تواريخ الأحداث: Date Created: 20220502 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9024375
DOI: 10.1016/j.csbj.2022.04.008
PMID: 35495118
قاعدة البيانات: MEDLINE
الوصف
تدمد:2001-0370
DOI:10.1016/j.csbj.2022.04.008